Revenue passed $94 billion, operating income hit $25.6 billion, and the MedTech segment is quietly compounding at double-digit rates while the market is still processing the Kenvue separation.
J&J reported fiscal 2025 revenue of $94.2 billion, operating income of $25.6 billion, and net income of $26.8 billion. The company generated $19.7 billion of free cash flow. At a market cap of $564 billion and 20x forward earnings, the valuation looks pedestrian for a healthcare bluechip. The reported numbers suggest the market is underpricing the mix shift that has already happened.
The specific thesis: following the 2023 Kenvue consumer health separation, J&J is a pure-play pharma-plus-MedTech business. The MedTech segment (Abiomed, DePuy Synthes orthopaedics, cardiology, surgical vision) is growing faster than the pharma segment and runs at higher margins than the market appreciates. The Research Desk view is that J&J is worth $260-280 per share on a standalone MedTech-pharma valuation framework, versus the $241 current price.
The April 19 MedTech data point release sparked fresh sell-side reassessment, which is likely to be the catalyst for the multiple to move toward fair value.
The August 2023 Kenvue separation removed approximately $15 billion of consumer healthcare revenue from J&J's top line, along with the associated consumer brand portfolio (Tylenol, Band-Aid, Listerine). The strategic logic was clean: consumer health was growing slower than the rest of J&J, operated at lower margins, and was consuming management attention disproportionate to its profit contribution.
The remaining business has two segments. Innovative Medicine (pharma) represents approximately 60% of revenue and includes Darzalex, Stelara, Tremfya, Erleada, and the rapidly growing oncology pipeline (multiple myeloma, lung cancer, bladder cancer). MedTech represents approximately 40% of revenue and spans medical devices across cardiology, orthopaedics, surgical, and vision.
The market's mental model of J&J has been slow to update. Many investors still think of J&J as the consumer-dominant healthcare conglomerate of the pre-Kenvue era. The current business is materially different. Innovative Medicine is one of the largest pharma franchises globally with a credible pipeline. MedTech is one of the largest medical device businesses globally with a growth acceleration underway.
Historically, healthcare conglomerates that have simplified their structures have seen multiple expansion following the transition. Pfizer's 2020 Viatris separation produced roughly 18 months of outperformance for the remaining business before the COVID cycle distorted the comparison. Merck's 2021 Organon separation produced similar outperformance. J&J's Kenvue separation is still in the early innings of that re-rating.
TickerXray Report
Get the complete Johnson & Johnson report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
The April 19 MedTech data release provided fresh visibility into segment performance. The key takeaways that have not fully propagated into sell-side models.
Cardiology MedTech grew approximately 18% in FY25, led by Abiomed (Impella heart pumps) and electrophysiology ablation platforms. The Abiomed acquisition, closed in December 2022 for $16.6 billion, has converted to revenue growth faster than the deal economics originally assumed. The electrophysiology portfolio, boosted by the Shockwave acquisition closed in 2024, is now the fastest-growing sub-segment within MedTech.
Orthopaedics grew approximately 6%, roughly in line with the market. The trajectory is less exciting than cardiology but produces stable gross margin contribution at roughly 65%. The segment benefits from favourable demographics (aging population, higher joint replacement rates) that compound over decades.
Surgical and vision each grew approximately 8-10%. Both segments have specific technology upgrades (robotic surgery platform rollout, vision care IOL mix improvement) driving share gain.
The blended MedTech growth rate is approximately 9-10%, compared to the historical 4-5% pre-acquisition pace. The segment margin has expanded from approximately 25% to closer to 29% as acquired businesses integrate. At current MedTech revenue of approximately $33 billion growing at 9% with expanding margins, the contribution to total company earnings is accelerating faster than the consolidated top-line suggests.
J&J has increased its dividend for 62 consecutive years. The current quarterly dividend is $1.30 per share, annualised $5.20, yielding 2.22%. The 5-year dividend growth rate is approximately 5%, which combined with buybacks produces a total shareholder return framework that consistently delivers mid-to-high single digits before any growth contribution.
Share count reduction is meaningful. J&J has reduced shares outstanding from approximately 2.63 billion in FY21 to approximately 2.40 billion in FY25, a 9% cumulative reduction. Most of this came through the Kenvue tax-efficient share exchange, but organic buybacks have continued at a modest pace.
The balance sheet is exceptional for a business of this scale. Net debt is approximately $20 billion against operating income of $25.6 billion. Debt-to-EBITDA is under 0.8x. The business has extraordinary flexibility to fund M&A (the Shockwave and Ambrx deals in recent years demonstrate the willingness) without capital structure concerns.
The FY25 operating cash flow of approximately $24.5 billion and FCF of $19.7 billion is stable year-on-year. The capital allocation framework is clear: dividend growth tracks FCF, buybacks fill in residually, and M&A is opportunistic when targets deliver IRRs above the internal pipeline. This is textbook capital-disciplined healthcare allocation.
Pharma segment comparison: Eli Lilly trades at 40x forward earnings, Novo Nordisk at 28x, Merck at 14x, Pfizer at 9x. J&J pharma's growth rate is higher than Merck and Pfizer, lower than Lilly and Novo. A fair standalone pharma multiple is 18-20x, implying pharma segment value of approximately $350-400 billion.
MedTech segment comparison: Medtronic trades at 18x forward, Stryker at 26x, Boston Scientific at 32x, Abbott at 23x. J&J MedTech's growth rate is closer to Boston Scientific and Stryker than to Medtronic. A fair standalone MedTech multiple is 22-25x, implying MedTech segment value of approximately $200-220 billion.
Sum-of-parts: $350-400B pharma + $200-220B MedTech = $550-620B total, less $20B net debt = $530-600B equity value, or $221-250 per share. The stock at $241 is at the midpoint of this SOTP range. The catalyst for further upside is MedTech margin expansion (currently running 29%, targeted 32% by FY27) and pharma pipeline successes.
The peer comparison that matters for FY26-FY27: Abbott had its own separation process (AbbVie spin-off) that created multiple expansion over a 3-5 year window. J&J post-Kenvue is in year 2 of a similar trajectory.
Three growth vectors compound through 2030.
First, the oncology pipeline. J&J has approximately 15 novel oncology compounds in clinical development, with 5 expected launches by 2028. The multiple myeloma franchise alone (Darzalex, Tecvayli, Talvey, Carvykti) is projected to exceed $20 billion in combined revenue by 2030.
Second, MedTech platform integration. Abiomed, Shockwave, and Ambrx have all been integrated into the MedTech platform over the last three years. The integration value (cross-selling, manufacturing economies, distribution leverage) typically takes 3-5 years to fully realise. The margin expansion from 25% to targeted 32% is the specific financial manifestation of this integration.
Third, geographic expansion. J&J's exposure to emerging markets (particularly China, India, Brazil) is underdeveloped relative to competitors. The build-out of MedTech distribution in these markets is a 10-year growth story. The recent regulatory approvals for key MedTech products in China specifically are quiet contributors that will show up in the 2027-2029 revenue profile.
The talc litigation overhang has largely been resolved through the 2023-2024 settlements. Remaining legal exposure is meaningful but bounded; reserves are adequately set aside and no new material claim inflection is expected.
The three material risks.
First, Stelara patent expiration. The biosimilar launch in the US market in 2025 is compressing Stelara revenue faster than modelled. Full-year FY26 impact is approximately $4-5 billion of revenue at risk, partially offset by transition to Tremfya. The net impact on FY26 EPS is approximately 2-3%.
Second, pharma pipeline setbacks. The FY25 pipeline had multiple late-stage readouts; not all will succeed. A single significant failure (particularly in oncology) would compress the long-duration growth story. The pipeline is broad enough that no single failure is thesis-breaking, but the cumulative probability of 2-3 setbacks in a given year is material.
Third, continued talc litigation. The 2023-2024 settlement framework covers most claims, but new claims or state-level actions continue to emerge. Legal costs remain a line item. The risk is more reputational than financial at this point, but reputational risk in healthcare can affect regulatory relationships over time.
J&J is a quality healthcare compounder at a reasonable valuation. The Kenvue separation reshaped the business into a higher-growth, higher-margin pharma-plus-MedTech operator. The market has been slow to adjust the valuation framework to match the new business structure.
Fair value on a sum-of-parts basis is $260-280 per share. Current $241 price is below this range. The 50-day moving average of $241 is at the low end of fair value; the stock has been range-bound as the market digests the post-Kenvue business and waits for clearer MedTech segment metrics.
Expected total return over 24 months: 15-20% from multiple expansion + 8-10% from organic earnings growth + 2.2% dividend yield = 25-32% cumulative. The dividend safety is exceptional (62-year track record, 1.6x cash coverage on FCF). The downside is limited because of the capital return floor.
Buy at current levels, accumulate on any weakness below $225. The MedTech data release last week was a specific catalyst for the re-rating that we expect will play out over the next 12-18 months. The Research Desk is overweight J&J in a diversified portfolio.
Full forensic analysis of Johnson & Johnson
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
The Q1 MedTech data is the line item the market was not pricing. Combined with a Stelara erosion curve that is shallower than the 2024 bear case assumed, the forward-earnings arithmetic changes.
JNJ has lifted from a 52-week low of $142 to the $234 range, a 64% move, while free cash flow has held at $19.7 billion and the pharma pipeline momentum has accelerated. The litigation overhang has not gone away, but the earnings power has stepped up.
With $19.7 billion in free cash flow, 72.8% gross margins, and a 64-year dividend streak, Johnson & Johnson's path through the Stelara cliff is better funded than the market appreciates.